Every 8-K that INNOVATE Corp. (VATE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow VATE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VATE filings page.
INNOVATE Corp. (VATE) has closed the previously announced sale of a controlling interest in its Broadcasting segment to CONX Corp. via the merger of HC2 Broadcasting Holdings Inc. into a CONX subsidiary, leaving CONX with 75% and INNOVATE with 25% of the surviving entity, subject to post‑closing adjustments. As part of the transaction, a $105 million bridge loan facility and accrued interest were extinguished, and CONX committed to fund up to $75 million of equity into HC2, with about $3.7 million funded at closing.
The filing also reports a Tenth Amendment to INNOVATE’s MSD Credit Agreement, extending its maturity to December 31, 2026. INNOVATE’s subsidiary holds an option for 18 months to acquire up to an additional 15% ownership in the HC2 surviving entity, while a CONX affiliate holds a two‑year option from May 29, 2026 to acquire up to 80.1% of HC2’s equity; INNOVATE will receive cash proceeds from the Broadcasting transaction only if that CONX affiliate option is exercised.
INNOVATE Corp. reported that MediBeacon Inc., an equity method investment focused on fluorescent tracer agents and transdermal detection, has had its MediBeacon® TGFR™ System nominated by The Galien Foundation for the 2026 Prix Galien USA Best Medical Technology. The TGFR System is a first-in-kind point-of-care kidney function assessment platform using Lumitrace® (relmapirazin) injection, a monitor, and a reusable sensor to measure Glomerular Filtration Rate transdermally. Winners are scheduled to be announced at the 20th annual Prix Galien USA Awards Ceremony on October 29, 2026, in New York City. MediBeacon holds extensive intellectual property around this system and related technologies, and the TGFR System is approved for human use, with additional applications in other medical fields in various stages of clinical development.
INNOVATE Corp. agreed to sell its approximately 91.21% stake in DBM Global Inc. to IES Holdings as part of a transaction valuing DBMG at $650 million, with customary closing adjustments. INNOVATE will receive about $453 million in cash and 215,487 IES common shares (valued at $140 million under the agreement), plus an additional $35 million cash tied to a Section 338 tax election.
The company plans to use all net cash proceeds and any sale proceeds from the stock consideration to repay its revolving credit facility, mandatorily redeem its 10.500% Senior Secured Notes due 2027, and then fund the required offer to purchase its 9.5% Convertible Senior Secured Notes due 2027 at 100% of principal plus accrued interest. Supplemental indentures modify note covenants so the DBMG sale is not an Asset Sale or Change of Control and require net cash proceeds to redeem the secured notes within 15 days and to fund the convertible note offer within 45 days of closing.
INNOVATE also put in place an at-the-market program with Jefferies to sell up to $31 million of common stock, paying a 3.0% commission on gross proceeds. Together with a separate Broadcasting disposition, the DBMG sale is expected to eliminate substantially all consolidated operating revenue and leave INNOVATE primarily with sale proceeds applied to debt, a minority interest in the post-merger broadcasting entity, its Life Sciences segment and limited other activities; the company warns past results will not be indicative of future performance and that it may temporarily qualify as an inadvertent investment company under the Investment Company Act.
INNOVATE Corp. reported a sharply improved second quarter for 2026. Consolidated revenue rose to $421.6 million, up 74.2% year over year, driven mainly by the Infrastructure segment. Net income attributable to common and participating preferred stockholders was $10.4 million, or $0.71 per diluted share, versus a $22.0 million loss a year earlier. Total Adjusted EBITDA increased to $46.3 million from $15.7 million.
DBM Global (Infrastructure) generated revenue of $414.0 million and grew reported and adjusted backlog to $1.9 billion and $2.7 billion. Life Sciences revenue declined to $2.2 million, while Spectrum revenue was $5.4 million with $8.4 million of net income helped by a refinancing-related gain on extinguishment of debt.
The company is pursuing “highly substantial” asset dispositions, including a potential sale of all or substantially all of DBMG and a majority interest in Broadcasting, and had total debt of $616.0 million at June 30, 2026. Risk disclosures note “substantial doubt about our ability to continue operating as a going concern” amid these planned transactions and its leveraged capital structure.
INNOVATE Corp. amended the indentures governing its 10.500% Senior Secured Notes due 2027 and 9.5% Convertible Senior Secured Notes due 2027 through supplemental indentures dated July 31, 2026. For consenting holders, interest for the period from February 1, 2026 through July 31, 2026 may be paid in kind by increasing principal or issuing additional Notes, and those holders receive a consent fee of 1.5% of principal in additional Notes. Non-consenting holders continue under existing cash interest terms.
For the August 1, 2026 interest payment, the outstanding principal of the 10.500% 2027 Senior Secured Notes will be $400.9 million, with cash interest of $3.1 million instead of $19.9 million. The outstanding principal of the 2027 Convertible Notes will be $58.9 million, with cash interest of $0.5 million instead of $2.7 million. Related party Lancer Capital LLC consented on its 2027 Convertible Notes and received an additional $0.1 million principal amount as payment in kind and consent fee. Separately, the maturity of the senior secured Lancer Note held by Lancer Capital LLC against R2 Technologies, Inc. was extended from August 1, 2026 to December 31, 2026.
INNOVATE Corp. announced that its portfolio company DBM Global Inc. (DBMG) plans to pay a cash dividend of approximately $12 million, or $3.12 per share. The dividend is payable on August 3, 2026 to DBMG stockholders of record as of the close of business on July 20, 2026.
As DBMG’s largest stockholder, INNOVATE expects to receive approximately $11 million of the total payout. INNOVATE’s own stockholders will not receive this dividend directly, as it is being paid at the DBMG subsidiary level.
Innovate Corp. reported the results of its Annual Meeting of Stockholders held on June 11, 2026. Stockholders elected four directors — Avram A. Glazer, Warren H. Gfeller, Brian S. Goldstein and Amy M. Wilkinson — to serve until the 2027 annual meeting.
Stockholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers and approved an amendment to the Second Amended and Restated 2014 Omnibus Equity Award Plan to increase the shares available for equity awards. In addition, they ratified the appointment of BDO USA, P.C. as independent registered public accounting firm for the fiscal year ending December 31, 2026.
INNOVATE Corp. has agreed to a merger transaction that will transfer control of its Broadcasting subsidiary to CONX Corp., subject to regulatory approvals. After closing, CONX is expected to own about 75% of Broadcasting, while INNOVATE will retain roughly 25% through HC2 Holdco.
To support the deal and clean up legacy debt, Broadcasting entered into a new $105 million bridge loan from a CONX subsidiary. The proceeds fully satisfied its 8.50% and 11.45% notes, funded repurchases of certain equity interests, and covered transaction costs. This bridge loan bears 8.00% annual interest, matures in one year and will be extinguished, rather than repaid in cash, when the merger closes, provided conditions are met.
CONX has also committed up to $75 million of post-closing equity funding for Broadcasting. INNOVATE obtained an 18‑month option to buy up to 15% of the surviving entity’s equity from CONX, while a CONX affiliate received a two‑year option to acquire up to 80.1% of Broadcasting’s equity on a fully diluted basis. INNOVATE amended its existing notes and credit agreement, with lenders consenting to the merger, the new loan and waiving related defaults.
INNOVATE Corp. reported stronger first quarter 2026 results, with consolidated revenue of $364.8 million, up 33.0% from $274.2 million a year earlier, driven mainly by its Infrastructure segment.
Net loss attributable to common and participating preferred stockholders improved to $17.2 million, or $1.29 per share, compared with $24.8 million, or $1.89 per share. Total Adjusted EBITDA rose sharply to $19.7 million from $7.2 million, helped by better performance in Infrastructure and reduced losses in Life Sciences.
Infrastructure subsidiary DBM Global generated revenue of $357.9 million, up 35.1%, and Adjusted EBITDA of $23.0 million, supported by large structural steel projects and reported backlog of $1.6 billion with adjusted backlog of $1.8 billion. Life Sciences saw MediBeacon obtain CE mark approval in Europe for its Transdermal GFR Monitor and Reusable Sensor, while R2’s international system sales grew. Spectrum revenue declined to $5.3 million and Adjusted EBITDA to $0.7 million amid softer advertising and network terminations.
INNOVATE Corp. reported that its portfolio company DBM Global Inc. (DBMG), an operating subsidiary providing integrated steel construction services, has declared a cash dividend of approximately $3 million, or $0.78 per share.
The dividend is scheduled to be paid on April 28, 2026 to DBMG stockholders of record as of the close of business on April 13, 2026. As DBMG’s largest stockholder, INNOVATE expects to receive approximately $2.7 million of the total dividend. The company clarified that INNOVATE’s own stockholders will not receive this cash dividend; it is paid only to DBMG’s stockholders.
INNOVATE Corp. reports that its equity method investment MediBeacon has received European Union CE Mark certification under the EU Medical Device Regulation 2017/745 for its TGFR Monitor and TGFR Reusable Sensor. This confirms the devices meet EU safety, quality, and performance standards.
The TGFR System combines the Monitor, Reusable Sensor, Disposable Ring, and Lumitrace (relmapirazin) injection to assess kidney function by measuring fluorescent tracer clearance through the skin, providing a transdermal measure of glomerular filtration rate. Lumitrace injection is approved in the U.S. and China, with an EU submission pending, and the system is already approved for human use by the U.S. FDA and China NMPA.
INNOVATE Corp. reported strong fourth-quarter 2025 growth but remained unprofitable. Revenue for the quarter rose to $382.7 million, up 61.7% from $236.6 million, driven mainly by the Infrastructure segment. Full-year revenue reached $1,246.0 million, up 12.5% from $1,107.1 million.
Quarterly net loss attributable to common and participating preferred stockholders narrowed to $7.8 million (loss of $0.58 per share) from $16.9 million (loss of $1.29 per share), though the full-year loss widened to $64.0 million from $35.8 million. Total Adjusted EBITDA improved in the quarter to $24.5 million from $15.0 million, but declined for the year to $67.2 million from $71.3 million.
Infrastructure revenue climbed to $373.9 million in Q4, with adjusted backlog of $1.8 billion, up from $1.1 billion a year earlier. In Life Sciences, MediBeacon received U.S. FDA approval for its next-generation TGFR system, while R2 delivered full-year 2025 revenue of $12.5 million, up 27.6%. Spectrum faced softer advertising and lower revenue, but cited favorable FCC rulings, new network launches and successful datacasting trials as 2026 growth drivers. Cash and cash equivalents rose to $112.1 million, while total debt stood at $661.7 million and stockholders’ deficit was $226.2 million.
INNOVATE Corp. reported that MediBeacon, in which it holds a 44.7% equity interest, had a peer-reviewed article on its transdermal GFR (tGFR) measurement recognized as one of five 2025 Editors’ Choice articles by the Journal of the American Society of Nephrology.
The featured work describes MediBeacon’s TGFR System, which uses the Lumitrace (relmapirazin) fluorescent tracer and a wearable sensor to measure kidney function through the skin at the point of care. The article was featured on the journal’s August 2025 cover.
The TGFR System is approved for human use, and commercialization through centers of excellence in select academic medical centers began in January 2026, initially focusing on heart failure monitoring, transplant evaluation and oncology drug dosing.
INNOVATE Corp. filed a current report to note that one of its portfolio companies, referred to as Global, plans to pay a cash dividend. The company disclosed this by issuing a press release titled “INNOVATE’s Portfolio Company Global to Pay Cash Dividend,” which is included as an exhibit.
The press release is attached as Exhibit 99.1 and is furnished rather than filed, meaning it is not automatically incorporated into other securities law filings. The report also includes the cover page interactive data file as Exhibit 104.
INNOVATE Corp. reported that on December 16, 2025 it issued a press release titled “MediBeacon® Next Generation TGFRTM System Receives FDA Approval,” announcing that this MediBeacon system has received FDA approval. This highlights a notable regulatory milestone for that product.
The company is sharing the news with investors through the press release, which is attached as Exhibit 99.1 and is not deemed filed for purposes of Section 18 of the Exchange Act or automatically incorporated into Securities Act filings. INNOVATE’s common stock, par value $0.001 per share, is listed on the New York Stock Exchange under the symbol VATE.
INNOVATE Corp. (VATE) furnished its Q3 2025 results update. The company announced results for the three and nine months ended September 30, 2025 via a press release and investor presentation, furnished under Items 2.02 and 7.01.
Exhibits include the Earnings Release (99.1) and Third Quarter 2025 Conference Call Investor Presentation (99.2). A conference call and simultaneous webcast are scheduled for November 12, 2025 at 4:30 p.m. ET on the Investor Relations section of the company’s website.
INNOVATE Corp. filed an 8-K announcing a press release titled “MediBeacon receives regulatory approval to sell the Transdermal GFR System in China.” The company states the press release is attached as Exhibit 99.1.
Exhibit 99.1 is furnished and not deemed filed under Section 18 of the Exchange Act, and it is not incorporated by reference into Securities Act filings unless specifically referenced.
INNOVATE Corp. filed an 8-K announcing that its portfolio company, DBM Global, plans to pay a cash dividend. The company issued a press release titled “INNOVATE’s Portfolio Company DBM Global to Pay Cash Dividend” on October 16, 2025, which is attached as Exhibit 99.1.
The press release is furnished and not deemed filed under Section 18 of the Exchange Act, nor incorporated by reference under the Securities Act unless specifically referenced in a future filing. INNOVATE’s common stock trades on the NYSE under the symbol VATE.
INNOVATE Corp. filed a current report to share a press release about one of its portfolio companies. On September 9, 2025, the company issued a release titled “INNOVATE’s Portfolio Company, R2, has Explosive Growth and Global Reach with Glacial® Skin Continuing to Redefine Aesthetic Innovation,” highlighting developments at R2 and its Glacial® Skin technology.
The press release is attached as Exhibit 99.1 and is treated as “furnished,” not “filed,” meaning it is not subject to certain liability provisions and is not automatically incorporated into other securities offerings unless specifically referenced. No new financial statements or major transactions are described in this report.
INNOVATE Corp. (NYSE: VATE) filed an 8-K to disclose preliminary results of its previously announced exchange offer and consent solicitation for its 8.5% Senior Secured Notes due 2026. According to the 31 July 2025 filing (Item 8.01), eligible holders that tendered their notes by 5:00 p.m. ET on 30 July 2025 will receive newly issued 10.5% Senior Secured Notes due 2027 plus the Total Early Exchange Consideration. The company also extended the ability to receive this early-bird consideration through the final Expiration Deadline, aiming to maximise participation. Numeric take-up levels and revised terms were not included in the filing but are expected in Exhibit 99.1 (press release). No other financial statements were furnished. The transaction lowers near-term refinancing pressure by pushing maturity out one year, but comes at a higher coupon, signalling a higher cost of capital.